Alternatives to Synthetic Biology Engineering

Biotechnology company leveraging ultracompact CRISPR systems for gene editing therapies and diagnostics.

LanzaTech transforms waste carbon emissions into valuable products like ethanol, SAF, and chemicals.

UK biotechnology company developing sustainable natural rubber from engineered dandelions.

Clinical-stage biopharmaceutical company leveraging a proprietary platform to discover and develop novel precision medicines from fungi.

A University of Cambridge spin-out tackling unmet drug screening needs by combining materials engineering and cell biology.

Pioneering Liquid State Intelligence for physical-world AI.

Engineering-driven DNA design platform to overcome biological barriers in genetic medicines.

Using microorganisms as programmable molecular factories for industrial ingredients.

Moderna is a biotechnology company pioneering mRNA medicine, best known for its COVID-19 vaccine and a broad pipeline of mRNA-based therapeutics.

Clinical-stage biopharmaceutical company developing next-generation antibody-drug conjugates (ADCs) for cancer treatment.

AI safety and research company building reliable, interpretable, and steerable AI systems.

Global biopharmaceutical company pioneering mRNA-based immunotherapies and vaccines for cancer and infectious diseases.

A life sciences company that has developed a high-throughput platform for mapping molecular cell architecture at nanoscale resolution.

Clinical-stage biotechnology company advancing molecular glue degrader (MGD) medicines.

Epicrispr Biotechnologies is a biotechnology company developing novel epigenetic therapies, with a lead program targeting Facioscapulohumeral Muscular Dystrophy (FSHD).

Global supplier of life science research tools, including antibodies, reagents, and assays.

Spatial multiomics company developing technologies for single-cell gene expression profiling in intact tissues.

A vertically-integrated procurement platform for the life sciences industry.

A clinical-stage biotechnology company developing inobrodib as a first-in-class, oral p300/CBP inhibitor for the treatment of multiple myeloma.